Jack A. Khattar - Sep 10, 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Sep 10, 2025
Transactions value $
$0
Form type
4
Date filed
9/12/2025, 04:05 PM
Previous filing
Sep 9, 2025
Next filing
Sep 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khattar Jack A. President, CEO, Director C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 2025-09-12 0001539937

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SUPN Common Stock 1.11M Sep 10, 2025 Direct
holding SUPN Common Stock 1.01M Sep 10, 2025 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Award $0 +20K $0.00 20K Sep 10, 2025 Common Stock 20K $0.00 Direct F1
transaction SUPN Performance Share Units Award $0 +19.3K $0.00 19.3K Sep 10, 2025 Common Stock 19.3K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021.
F2 On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.